Skip to main content

Table 1 The baseline characteristics of the included studies

From: Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients’ data analysis for outcome and effectiveness of the current regimens

Study area First author, year of publication Study period Study design No of MDR-TB cases Types of cases Method Treatment category HIV status
Northeastern Ethiopia Baye et al, 2018 [20] 2012–2016 RC 141 Pulmonary tuberculosis (96.5%)
Extra-pulmonary tuberculosis (3.5%)
Line probe assay
Culture
Xpert MTB/RIF
New (8.5%)
Relapse (13.5%)
After lost to follow up (2.1%)
Failure of a new regimen (30.5%)
After the failure of retreatment (42.6%)
Transfer in from other sites (1.4%)
Other (1.4%)
HIV co-infected, 38 (27%), the majority of the patients have received ART (84.2%)
Southern Ethiopia Girum et al, 2017 [21] 2009 to 2014 RC 154 Pulmonary tuberculosis (94%)
Extra-pulmonary tuberculosis (6%)
Culture
Xpert MTB/RIF
History of previous treatment (90%)
New cases (10%)
HIV co-infection, 11 (7.2%), of them 9 have had a history of previous treatment
Northwest Ethiopia Alene et al, 2017 [22] 2010 to 2015 RC 242 Pulmonary tuberculosis (94%)
Extra-pulmonary tuberculosis (6%)
Culture
Xpert MTB/RIF
History of previous treatment (93%)
New cases (7%)
HIV co-infection, 51 (21.1%)
Central Ethiopia Mequanint et al., 2014 [23] 2011 to 2013 DRC 680 Pulmonary tuberculosis (84%)
Extra-pulmonary (15.6%)
Both, 0.4%
Culture History of previous treatment, 35% HIV co-infection, 193 (28.4%)
Eastern Ethiopia Tolera et al. 2018 [24] 2005 to 2016 DRC 164 Pulmonary tuberculosis (98.2%)
Extra-pulmonary tuberculosis (1.8%)
Retreated cases, 97% HIV co-infection, 41 (25%), the majority of the patients have received ART (97.6%)
Central and Northwest Ethiopia Meressa et al., 2015 [25] 2009 to 2014 PC 612 Pulmonary tuberculosis (93%)
Extra-pulmonary tuberculosis (7%)
Culture
Line probe assay
History of previous treatment (98.5%)
HIV infection (21.7%)
HIV co-infection, 133 (21.7%), the median CD4 count was 239 cells/ml3, the majority of the patients have received ART (90.2%)
  1. Key: RC retrospective cohort study, DRC descriptive retrospective cross-sectional study, PC prospective cohort study
\